CO6270229A2 - Derivados de tiazol fusionados como inhibidores de quinasa - Google Patents

Derivados de tiazol fusionados como inhibidores de quinasa

Info

Publication number
CO6270229A2
CO6270229A2 CO09149835A CO09149835A CO6270229A2 CO 6270229 A2 CO6270229 A2 CO 6270229A2 CO 09149835 A CO09149835 A CO 09149835A CO 09149835 A CO09149835 A CO 09149835A CO 6270229 A2 CO6270229 A2 CO 6270229A2
Authority
CO
Colombia
Prior art keywords
fusionated
derivatives
tiazol
inhibitors
quinasa
Prior art date
Application number
CO09149835A
Other languages
English (en)
Spanish (es)
Inventor
Rikki Peter Alexander
Pavandeep Singh Aujla
Karen Viviane Crepy
Anne Marie Foley
Richard Jeremy Franklin
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0612644A external-priority patent/GB0612644D0/en
Priority claimed from GB0620062A external-priority patent/GB0620062D0/en
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Publication of CO6270229A2 publication Critical patent/CO6270229A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CO09149835A 2006-06-26 2009-12-31 Derivados de tiazol fusionados como inhibidores de quinasa CO6270229A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0612644A GB0612644D0 (en) 2006-06-26 2006-06-26 Therapeutic agents
GB0620062A GB0620062D0 (en) 2006-10-10 2006-10-10 Therapeutic agents
PCT/GB2007/002390 WO2008001076A1 (en) 2006-06-26 2007-06-26 Fused thiazole derivatives as kinase inhibitors

Publications (1)

Publication Number Publication Date
CO6270229A2 true CO6270229A2 (es) 2011-04-20

Family

ID=38671000

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09149835A CO6270229A2 (es) 2006-06-26 2009-12-31 Derivados de tiazol fusionados como inhibidores de quinasa

Country Status (20)

Country Link
US (3) US8242116B2 (cg-RX-API-DMAC10.html)
EP (2) EP2035436B1 (cg-RX-API-DMAC10.html)
CN (1) CN101687885B (cg-RX-API-DMAC10.html)
AT (1) ATE510840T1 (cg-RX-API-DMAC10.html)
AU (1) AU2008269577B2 (cg-RX-API-DMAC10.html)
CA (1) CA2692085C (cg-RX-API-DMAC10.html)
CO (1) CO6270229A2 (cg-RX-API-DMAC10.html)
CY (1) CY1114419T1 (cg-RX-API-DMAC10.html)
DK (1) DK2170906T3 (cg-RX-API-DMAC10.html)
EA (1) EA017187B1 (cg-RX-API-DMAC10.html)
ES (2) ES2365258T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20130523T1 (cg-RX-API-DMAC10.html)
IL (1) IL202659A0 (cg-RX-API-DMAC10.html)
ME (1) ME01592B (cg-RX-API-DMAC10.html)
MX (1) MX2009013740A (cg-RX-API-DMAC10.html)
MY (1) MY148852A (cg-RX-API-DMAC10.html)
PL (1) PL2170906T3 (cg-RX-API-DMAC10.html)
PT (1) PT2170906E (cg-RX-API-DMAC10.html)
RS (1) RS52824B (cg-RX-API-DMAC10.html)
WO (1) WO2008001076A1 (cg-RX-API-DMAC10.html)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009071890A1 (en) * 2007-12-04 2009-06-11 Ucb Pharma S.A. Tricyclic kinase inhibitors
WO2009071895A1 (en) * 2007-12-04 2009-06-11 Ucb Pharma S.A. Fused thiazole and thiophene derivatives as kinase inhibitors
AU2008343932B2 (en) 2007-12-19 2013-08-15 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
ATE531372T1 (de) 2008-04-07 2011-11-15 Amgen Inc Gem-disubstituierte und spirocyclische aminopyridine/pyrimidine als zellcyclus- inhibitoren
JPWO2009130900A1 (ja) * 2008-04-24 2011-08-11 日本曹達株式会社 オキシム誘導体、中間体化合物および植物病害防除剤
US8603945B2 (en) * 2008-07-23 2013-12-10 The Regents Of The University Of California Methods and compositions for providing salicyclic acid-independent pathogen resistance in plants
EP2341052A4 (en) * 2008-09-05 2011-10-12 Shionogi & Co RING-CONDENSED MORPHOLINE DERIVATIVITY WITH PI3K-INHIBITING EFFECT
AU2010216219A1 (en) 2009-02-17 2011-09-01 Vertex Pharmaceuticals Incorporated Tetrahydrothiazolopyridine inhibitors of phosphatidylinositol 3-kinase
AR076126A1 (es) * 2009-03-18 2011-05-18 Schering Corp Compuestos biciclicos como inhibidores de diacilglicerol aciltransferasa
UY32582A (es) * 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
ES2638323T3 (es) * 2009-05-20 2017-10-19 Glaxosmithkline Llc Derivados de tiazolopirimidinona como inhibidores de PI3 quinasa
GB0912946D0 (en) 2009-07-24 2009-09-02 Addex Pharmaceuticals Sa New compounds 5
MX2012002059A (es) 2009-08-20 2012-04-19 Karus Therapeutics Ltd Compestos heterociclicos triciclicos como inhibidores de fosfoionositida 3-quinasa.
EA020010B1 (ru) * 2009-12-18 2014-07-30 Янссен Фармацевтика Нв БИЦИКЛИЧЕСКИЕ ТИАЗОЛЫ В КАЧЕСТВЕ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ mGluR5 РЕЦЕПТОРОВ
ES2431302T3 (es) 2009-12-18 2013-11-25 Janssen Pharmaceutica, N.V. Tiazoles bicíclicos como moduladores alostéricos de receptores mGluR5
EP2582693B1 (de) 2010-06-15 2016-03-30 Bayer Intellectual Property GmbH Neue ortho-substituierte arylamid-derivate
BR112013007056A2 (pt) 2010-10-01 2019-09-24 Basf Se compostos de imina
AU2011316016A1 (en) * 2010-10-13 2013-05-30 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
BR112013012961A2 (pt) * 2010-11-24 2019-09-24 Exelixis Inc benzoxazepinas como inhibidores de mtor e métodos de seu uso e fabricação
CN102649777B (zh) * 2011-02-25 2014-03-12 中国中化股份有限公司 一种制备1-芳基-3-羧基-5-吡唑啉酮类化合物的方法
WO2012129344A1 (en) 2011-03-23 2012-09-27 Amgen Inc. Fused tricyclic dual inhibitors of cdk 4/6 and flt3
JO3398B1 (ar) 2011-12-22 2019-10-20 Novartis Ag مشتقات 2،3- ثانى هيدرو- بنزو[1,4] أوكسازين والمركبات المتعلقة بها كمثبطات كيناز فسفواينوسيتيد-3 (pi3k) لمعالجة على سبيل المثال التهاب المفاصل الروماتيدي
US9447079B2 (en) 2013-03-14 2016-09-20 Epizyme, Inc. PRMT1 inhibitors and uses thereof
US9023883B2 (en) 2013-03-14 2015-05-05 Epizyme, Inc. PRMT1 inhibitors and uses thereof
US9120757B2 (en) 2013-03-14 2015-09-01 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9133189B2 (en) 2013-03-14 2015-09-15 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US20160039767A1 (en) 2013-03-14 2016-02-11 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
US9365527B2 (en) 2013-03-14 2016-06-14 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2014153208A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
EP2970220A2 (en) 2013-03-14 2016-01-20 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
BR112015022785A2 (pt) 2013-03-14 2017-07-18 Epizyme Inc composto; composição farmacêutica; kit ou artigo farmacêutico embalado; método de inibição de uma arginina metil transferase (rmt); método de modulação da expressão genética; método de modulação da transcrição; e método de tratamento de um distúrbio mediado por rmt
CA2903264A1 (en) 2013-03-14 2014-11-06 Epizyme, Inc. Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof
WO2015059049A1 (de) * 2013-10-21 2015-04-30 Umicore Ag & Co. Kg Monoarylierung aromatischer amine
GB201402431D0 (en) 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
GB201514760D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds and method of use
GB201514758D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Formulation
GB201514754D0 (en) * 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
CN108570043A (zh) * 2018-06-20 2018-09-25 王延娇 一种化合物及其作为选择性pi3k抑制剂在治疗肿瘤中的应用
US20220202824A1 (en) 2018-09-13 2022-06-30 Stemline Therapeutics, Inc. Methods for Treating Centronuclear Myopathy
AU2019410261B2 (en) 2018-12-19 2025-10-02 Leo Pharma A/S Amino-acid anilides as small molecule modulators of IL-17
BR112021013105A2 (pt) * 2019-01-08 2021-09-21 Kyorin Pharmaceutical Co., Ltd. Inibidor de 15-pgdh
JP7532385B2 (ja) 2019-01-31 2024-08-13 杏林製薬株式会社 １５－ｐｇｄｈ阻害薬

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0508471D0 (en) 2005-04-26 2005-06-01 Celltech R&D Ltd Therapeutic agents

Also Published As

Publication number Publication date
AU2008269577B2 (en) 2012-12-20
ATE510840T1 (de) 2011-06-15
EA201000038A1 (ru) 2010-06-30
US8338592B2 (en) 2012-12-25
AU2008269577A1 (en) 2008-12-31
MY148852A (en) 2013-06-14
ME01592B (me) 2014-09-20
ES2416364T3 (es) 2013-07-31
EP2170906B1 (en) 2013-04-03
US20130079330A1 (en) 2013-03-28
PL2170906T3 (pl) 2013-08-30
US8710054B2 (en) 2014-04-29
EA017187B1 (ru) 2012-10-30
EP2035436A1 (en) 2009-03-18
IL202659A0 (en) 2010-06-30
CA2692085A1 (en) 2008-12-31
ES2365258T3 (es) 2011-09-27
EP2035436B1 (en) 2011-05-25
CN101687885A (zh) 2010-03-31
PT2170906E (pt) 2013-06-25
US8242116B2 (en) 2012-08-14
US20110003785A1 (en) 2011-01-06
CA2692085C (en) 2015-10-13
DK2170906T3 (da) 2013-06-24
HRP20130523T1 (en) 2013-07-31
MX2009013740A (es) 2010-02-01
EP2170906A1 (en) 2010-04-07
CY1114419T1 (el) 2016-08-31
US20100137302A1 (en) 2010-06-03
RS52824B (cg-RX-API-DMAC10.html) 2013-10-31
CN101687885B (zh) 2012-08-22
WO2008001076A1 (en) 2008-01-03

Similar Documents

Publication Publication Date Title
CO6270229A2 (es) Derivados de tiazol fusionados como inhibidores de quinasa
MY146387A (en) Thieno-pyridine derivatives as mek inhibitors
GB0508471D0 (en) Therapeutic agents
WO2009081105A3 (en) Quinoxaline and quinoline derivatives as kinase inhibitors
SMT201600089B (it) Composti di 3,4-diidropirazino[2,3-b]pirazin-2(1 h)-one come inibitori di chinasi mtor per indicazioni oncologiche e malattie associate al percorso mtor/p13k/akt
NI201800141A (es) Moduladores alostéricos positivos del receptor muscarínico de acetilcolina m4
CL2008003280A1 (es) Compuestos derivados de 1h-pirazolo[3,4-b]piridina)-4-aril sustituidas; la composicion farmaceutica que los contiene; y sus procesos de preparacion.
BR112016011484A2 (pt) Derivados de imidazopirimidina como moduladores de atividade de tnf
EP3489238B8 (en) Pharmaceutical compositions of 6h-pyrido[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-one and [1,2,4]triazolo[1,5-c]pteridin-5(6h)-one derivatives as pde1 inhibitors for treating e.g. neurological disorders
MX380578B (es) Derivados de imidazol pentaciclicos fusionados.
BRPI0722088A2 (pt) derivados de pirrolo[2,3-b]piridina como moduladores de cinase
WO2010052448A3 (en) Fused pyrazine derivatives as kinase inhibitors
EP3542629A3 (en) Dithiol compounds, derivatives, and uses therefor
WO2008020206A3 (en) Fused thiophene derivatives as mek inhibitors
BR112013015430A2 (pt) derivados de 5,6-diidro-imidazo[1,2-a]pirazin-8-ilamina úteis como inibidores de beta-secretase (bace)
BR112012002110A2 (pt) derivados de pirrolo[1,2-b]piridazina como inibidores de janus cinase
GT201400213A (es) Inhibidores de diacilglicerol aciltransferasa 2
NO20081133L (no) Tieno[2,3-B]-pyridin-5-karbonitriler som protein kinase inhibitorer
CL2012001027A1 (es) Compuestos derivados de 7-(fenilamina)-5-oxo-1,2,3,5-tetrahidro-imidazo[1,2-a]piridina, 7-(fenilamina)5-oxo-2,3-dihidro-5h-tiazolo[3,2-a]piridina, 7-(fenulaminas)-5-oxo-2,3-dihidro-2hoxazolo[3,2-a]piridina: composicion farmaceutica; utiles en el tratamiento de enfermedades, trastornos o sindrome asociado con la inhibicion mek.
CO6220934A2 (es) Derivados de imidazolidinacaboxamida como inhibidores de lipasas y foffolipasas
BR112016012254A2 (pt) Derivados de triazolpiridazina como moduladores de atividade de tnf
BR112016029635A2 (pt) derivados pirazolo-piridina como inibidores de quinase
UA99469C2 (ru) Конденсированные производные тиазола как ингибиторы киназы
EP3851439A4 (en) Furo[3,4-b]pyrrole-containing btk inhibitor
UY32280A (es) DERIVADOS DE 6-CICLOAMINO-3-(1H-PIRROLO[2,3-b]PIRIDIN-4-IL)IMIDAZO[1,2-b]-PIRIDAZINA, SU PREPARACIÓN Y SU APLICACIÓN EN TERAPÉUTICA

Legal Events

Date Code Title Description
FG Application granted